Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeat-containing protein 31 (LRRC31) is a nuclear protein characterized by multiple leucine-rich repeat motifs, forming a horseshoe-like structure that mediates protein-protein interactions essential for DNA damage response. LRRC31 specifically inhibits non-homologous end joining (NHEJ) DNA double-strand break repair through direct interaction with ATR and Ku70/Ku80 complex, impacting the recruitment and activation of DNA-PKcs and interfering with the MSH2-ATR signaling module. In epithelial tissues, LRRC31 is induced by IL-13 and enhances epithelial barrier function, in part by downregulating multiple kallikrein-related serine proteases (KLKs). LRRC31 is implicated in human diseases including cancer (as a tumor suppressor and radiosensitizing factor in breast cancer brain metastasis) and inflammatory disorders like eosinophilic esophagitis (where it may serve as an early biomarker of response to therapy)[1][3].
As a radiosensitizing gene, modulation of LRRC31 inhibits DNA repair protein recruitment and disrupts downstream signaling pathways (e.g., ATR-MSH2 complex) leading to increased radiosensitivity of cancer cells[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Leucine-rich repeat-containing protein 31 (LRRC31).